Two international clinical trials led in part by researchers at the University of Pittsburgh School of Medicine found that the investigational biologic therapy tozorakimab significantly reduced chronic obstructive pulmonary disease (COPD) flare-ups among patients already receiving standard treatment for the disease compared to patients only receiving standard treatment.

Two international clinical trials led in part by researchers at the University of Pittsburgh School of Medicine found that the investigational biologic therapy tozorakimab significantly reduced chronic ...